Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that a poster examining the effects of TONMYA (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The presentation comes as Tonix seeks to solidify TONMYA's position as the first new treatment for fibromyalgia in more than 15 years.
TONMYA received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025. The upcoming data presentation is significant because it will provide the first peer-reviewed forum for discussing the drug's impact on symptoms and physical function since its approval, potentially influencing prescribing practices and payer coverage decisions. For patients with fibromyalgia, a condition that has seen limited innovation, the data could offer validation of a new therapeutic option.
Tonix is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace SymTouch and Tosymra. Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The IASP World Congress is a leading global forum for pain research and clinical practice, and presenting TONMYA data there could raise the drug's profile among specialists and researchers. For investors, the event may serve as a catalyst for broader awareness of Tonix's pipeline. The full press release is available at https://ibn.fm/jFHh3, and the latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
The announcement was distributed through TinyGems, a communications platform focused on small-cap and mid-cap companies and part of the Dynamic Brand Portfolio at IBN. The platform provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For full terms and disclaimers, see https://www.TinyGems.com/Disclaimer.
